Experienced and certified Medical Assistant specializing in clinical trial management, data collection, and adverse event reporting. Skilled in patient recruitment and informed consent processes. Proven ability to collaborate effectively with medical professionals to ensure adherence to protocols and regulatory guidelines. Organized and dependable candidate adept at managing multiple priorities with a positive attitude. Willing to take on added responsibilities to meet team goals.
Study History
2025-Present
NCT03897374/CGx-02252019
Clinlogic Research-Strategic Targeting for Optimal Prevention of Cancer
The primary goal of the study is to record data over the observation period to evaluate the clinical benefit of using hereditary
cancer genomic diagnostics to assess overall hereditary genetic cancer risk profile and to help guide physicians to pursue
preventative measures, which may lead to early detection and treatment of the condition
2025-Present
Sleep Disturbance in Woman Experiencing Menopause
AlphaDetail/ IQVIA Menopause-Sleep disturbance
The objective of this study are to evaluate the burden of sleep disturbances in menopause, and the impact this may have on
people's quality of life. This study will look at any unmet need for new, effective, and safe treatments for sleep disturbances
associated with menopause. This study will take place over 28 days. During this time, the subjects will fill out surveys at
regular time points and keep a daily diary about their sleep and any symptoms experienced during the night. All of this will
be done on the easy-to-use digital platform.
2022-2024
NCT05643573/OCEANIC-AF 19767
BAYER-Atrial Fibrillation
A phase 3, multicenter, international, randomized, active comparator-controlled, double-blind, double dummy, parallel-group,
2-arm study to compare the efficacy and safety of the oral FXIa inhibitor Asundexian (BAY 2433334) with apixaban for the
prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at
risk for stroke.
2022-2023
NCT05238025/ BN RSV-MVA-004
Bavarian Nordic-RSV Vaccine
Phase 3
Double blind study comparing recombinant MVA-BN-RSV vaccine vs placebo for efficacy and safety in adults >=60 years of
age.
2021-Present
NCT05035212/ C3671013
Renoir- RSV Vaccine
A phase 3, multicenter, randomized, double-blinded, placebo-controlled study to assess the safety, immunogenicity, and
efficacy of RSV preF or placebo (1:1 randomization) in adults. This will be a global study that will span multiple RSV
seasons.
2021-2021
NCT04501952 / GS-US-540-9012
Gilead Sciences - COVID 19
PHASE 3
Study to evaluate the efficacy and safety of Remdesivir (GS-5734) Treatment of Coronavirus Disease 2019 (COVID-19) in an
outpatient setting
2017-2021
NCT03090191 / B5091007
CLOVER- Clostridium Difficile Infection Vaccine
A phase 3, placebo-controlled, randomized, observer-blinded study to evaluate the efficacy, safety, and tolerability of a
Clostridium difficile vaccine in adults 50 years of age and older.
2018-2022
NCT03518034 / M16-100
TRAVERSE- Hypogonadism, Cardiovascular Disease
PHASE 3
Testosterone Replacement Therapy for assessment of long-term vascular events and efficacy response in hypogonadal men.